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  31 
Abstract (Word Count 150)  32 
Type 2 diabetes can be treated, and sometimes reversed, with dietary interventions; however, 33 
strategies to implement these interventions while addressing medication changes are lacking. We 34 
conducted a 12-week pragmatic, community-based parallel-group randomized controlled trial 35 
(ClinicalTrials.gov: NCT03181165) evaluating the effect of a low-carbohydrate (<50g), energy-36 
restricted diet (~850-1100 kcal/day; Pharm-TCR; n=98) compared to treatment-as-usual (TAU; 37 
n=90), delivered by community pharmacists, on glucose-lowering medication use, 38 
cardiometabolic health, and health-related quality of life. The Pharm-TCR intervention was 39 
effective in reducing the need for glucose-lowering medications through complete 40 
discontinuation of medications (35.7%; n=35 vs. 0%; n=0 in TAU; p<0.0001) and reduced 41 
medication effect score compared to TAU. These reductions occurred concurrently with 42 
clinically meaningful improvements in hemoglobin A1C, anthropometrics, blood pressure, and 43 
triglycerides (all p<0.0001). These data indicate community pharmacists are a viable and 44 
innovative option for implementing short-term nutritional interventions for people with type 2 45 
diabetes, particularly when medication management is a safety concern. 46 
47 
Introduction 48 
Type 2 diabetes is typically considered a chronic progressive disease, but it is now established 49 
that reversal/remission of type 2 diabetes is possible. Targeted nutritional approaches have 50 
garnered attention due to the increasing evidence base suggesting they can be used to induce type 51 
2 diabetes reversal/remission1–3. In a non-randomized trial, continuous remote-care using a very 52 
low-carbohydrate, high-fat, ketogenic diet led to substantial weight loss, lowered haemoglobin 53 
A1C (HbA1c), and reduced need for glucose-lowering medications (including insulin) in a 54 
diverse group of 262 patients with type 2 diabetes4–6. In a cluster randomized controlled trial 55 
(RCT), Lean and colleagues7 showed that a 12-week very low-calorie (~850 kcal day) total diet 56 
replacement method followed by food reintroduction resulted in remission of type 2 diabetes 57 
(sub-diabetes HbA1c and taking no glucose-lowering medications) in 46% of newly diagnosed 58 
patients at one year follow-up. Online self-management interventions also report reduced oral 59 
diabetes medications and insulin dose, while lowering HbA1c, in participants with type 2 60 
diabetes8. The idea that diet therapy could reduce or eliminate the need for glucose-lowering 61 
medications is intriguing but raises several important issues in diabetes care, including 1) how to 62 
limit the risk of hypoglycemia due to contemporaneous over-medication; and 2) the lack of 63 
guidance and/or knowledge of how to safely manage medication reductions when patients follow 64 
very low-carbohydrate or low-calorie diets. 65 
While physicians are typically at the centre of diabetes care, pharmacists are more accessible and 66 
patients with type 2 diabetes make more annual visits to their pharmacist than primary care 67 
physician; this is especially true in rural areas9. Community pharmacists have expertise in 68 
medication management and can serve an important role in overall diabetes management10. Due 69 
to the need to reduce or eliminate glucose-lowering medications when type 2 diabetes patients 70 
follow a very low-carbohydrate or low-calorie diet4,7,11, community pharmacists may be ideally 71 
positioned to safely and effectively deliver nutrition interventions targeted at reducing diabetes 72 
medication use and promoting type 2 diabetes remission. Accordingly, the aim of the 73 
Pharmacist-led therapeutic carbohydrate restriction (Pharm-TCR) as a treatment strategy for type 74 
2 diabetes trial12 was to determine if a very low-carbohydrate, low-calorie diet - led by 75 
community pharmacists - could reduce the need for glucose-lowering medications and facilitate 76 
improvements in cardiometabolic health when compared to guideline-based treatment-as-usual 77 
(TAU).  78 
 79 
Results 80 
Baseline characteristics of study participants  81 
Between July 7th 2017 and April 1st 2019, we recruited 188 individuals from 12 pharmacies 82 
across southern British Columbia, Canada. Sample size fell just short of the target recruitment of 83 
100 per group; 98 participants randomized to the Pharm-TCR group and 90 participants 84 
randomized to the TAU group comprised the intention-to-treat population. Four participants in 85 
the Pharm-TCR group and 15 participants in the TAU group dropped out prior to commencing 86 
the trial. Furthermore, 16 participants in the Pharm-TCR group and 15 participants in the TAU 87 
group dropped out after commencing the trial. Sex assignment was missing for 13 participants. 88 
The CONSORT Flow Diagram is shown in Figure 1. Baseline participant characteristics are 89 
reported in Table 1.  90 
 91 
 92 
Table 1: Baseline characteristics 
Pharm-TCR TAU 
Sex   
Male (%) 44 43 
Female (%) 56 57 
Age (years) 58 (11) 59 (8) 
T2D Duration (years) 11.8 (8.0) 8.8 (8.0) 
Body weight (kg) 102.3 (21.6) 103.4 (19.7) 
BMI (kg/m2) 36.0 (6.0) 35.1 (5.3) 
Waist Circumference (cm) 115.6 (13.6) 115.8 (16.3) 
Body Fat % 39.0 (6.3) 40.2 (6.3) 
Systolic Blood Pressure (mmHg) 138 (17) 136 (16) 
Diastolic Blood Pressure (mmHg) 80 (14) 82 (13) 
HbA1c (%; percentage points) 7.9 (1.5) 7.8 (1.4) 
HbA1c (mmol/mol) 63 (16) 61 (15) 
Fasting Glucose (mmol/L) 9.3 (3.2) 9.3 (3.1) 
GGT (mmol/L) 40.8 (39.6) 47.8 (42.6) 
AST (mmol/L) 24.1 (13.9) 31.1 (21.5) 
ALT (mmol/L) 31.3 (20.0) 42.8 (30.5) 
HDL Cholesterol (mmol/L) 1.21 (0.32) 1.21 (0.31) 
LDL Cholesterol (mmol/L) 2.38 (0.95) 2.49 (0.98) 
Total Cholesterol (mmol/L) 4.46 (1.15) 4.56 (1.13) 
Triglycerides (mmol/L) 1.97 (1.47) 2.0 (1.02) 
CRP (mmol/L) 5.1 (5.3) 5.5 (5.1) 
Medication Effect Score 2.1 (1.7) 1.8 (1.7) 
Leisure Score Index 22.2 (26.7) 23.7 (21.7) 
Health Related Quality of Life   
Physical Functioning 70.1 (28.8) 69.6 (28.2) 
Role Functioning 71.9 (39.1) 71.7 (40.7) 
Social Functioning 81.3 (27.9) 84.4 (25.4) 
Mental Health 76.7 (16.6) 74.4 (16.3) 
Health Perceptions 52.8 (24.4) 49.2 (23.6) 
Pain 41.6 (27.0) 47.6 (21.3) 
Data are mean (SD). T2D: Type 2 diabetes; BMI: Body mass index; 
GGT: Gamma-glutamyl transferase; AST: Aspartate 
aminotransferase; ALT: Alanine aminotransferase; HDL: High-
density lipoprotein; LDL: Low-density lipoprotein; CRP: C-reactive 
protein 
 93 
Pharm-TCR led to greater discontinuation and reduction of glucose-lowering medication use  94 
At 12-weeks, 35.7% of participants in the Pharm-TCR group were completely off all glucose-95 
lowering medications compared to 0% in the TAU group (absolute difference = 35.7%, 95% CI 96 
25.9 to 44.8%, p<0.0001). Within the Pharm-TCR group, 17.3% of participants achieved a 97 
HbA1c of <6.5% (i.e., below the diagnostic threshold for diabetes diagnosis) and were not taking 98 
any glucose-lowering medications compared to 0% in the TAU group (absolute difference = 99 
17.3%, 95% CI 9.7 to 24.7%, p<0.0001). Exploratory subgroup analyses for the primary 100 
endpoint of no medications by sex and insulin user status are presented in Supplementary Table 101 
1. Changes in glucose lowering medications and blood pressure lowering medications, separated 102 
by medication class, are displayed in Supplementary Tables 3 and 4, respectively. To 103 
compliment the binary primary outcome, the Pharm-TCR group had lower mean medication 104 
effect score (MES) at 12 weeks (p<0.0001; Table 2). Weekly MES in the Pharm-TCR group is 105 




Pharm-TCR led to improvements in cardiometabolic health, anthropometrics, and health-related 110 
quality of life (HrQL)  111 
Secondary outcomes are reported in Table 2. Among clinical blood markers, HbA1c, fasting 112 
glucose, triglycerides, and GGT at 12 weeks were all lower in the Pharm-TCR versus TAU 113 
group (all p<0.0001). Mean body weight, body mass index (BMI), waist circumference, body fat 114 
percentage, and systolic and diastolic blood pressure were also lower at 12 weeks in the Pharm-115 
TCR group when compared to TAU (all p<0.0001). For measures of HrQL, role functioning, 116 
mental health, health perceptions, and pain all improved in the Pharm-TCR group versus TAU 117 
(p<0.05). Descriptive outcomes assessed weekly in the Pharm-TCR group are displayed in 118 
Figure 2.  Mean daily macronutrient and kilocalorie intake at baseline, week 6, and week 12 are 119 
reported in Supplementary Table 5. 120 
 121 
The exploratory statistical mediation analysis for the HbA1c (%) outcome revealed an indirect 122 
treatment effect (mediated via the change in body mass) of -0.8 (95% confidence interval: -1.3 to 123 
-0.3) percentage points (P=0.001). This mediation effect represents 57% of the total causal effect 124 
of -1.4 percentage points (Table 2). The direct effect (not mediated by the change in body mass) 125 
was -0.6 (-1.2 to -0.04) percentage points (P=0.037). 126 
 127 
Adverse events  128 
There were four adverse events reported in the Pharm-TCR group and no adverse events reported 129 
in the TAU group. Two of the adverse events were related to mild hypoglycemic events 130 
(recorded blood glucose levels of 4.1 mmol/L and 3.5 mmol/L); both events occurred when 131 
participants were reluctant to reduce insulin dosages by the recommended amount (one at the 132 
instruction of their endocrinologist) and were treated by the participants by consuming 133 
carbohydrates upon advice of their pharmacist. Upon following the recommended medication 134 
adjustments, these participants reported no more hypoglycemic symptoms. One adverse event 135 
was related to reporting hypoglycemic symptoms; however, the participant recorded blood 136 
glucose values no lower than 5.2 mmol/L. The cause of these symptoms was suggested to 137 
waiting too long between meals. Upon resolution of this issue, all hypoglycemic symptoms 138 
stopped. The final adverse event was a cardiac event that occurred three weeks into the study and 139 
was deemed not related to the intervention by the data safety monitoring board. 140 
 141 
Table 2: Secondary outcomes measured at 12-week follow-up 
Pharm-TCR TAU Treatment Effect p value 
Body weight (kg) 91.9 103.9 -12.0 (-13.6 to -10.4) <0.0001 
BMI (kg/m2) 31.2 35.6 -4.4 (-5.0 to -3.7) <0.0001 
Waist Circumference (cm) 102.4 113.8 -11.4 (-13.1 to -9.7) <0.0001 
Body Fat % 35.0 38.6 -3.7 (-5.0 to -2.5) <0.0001 
Systolic Blood Pressure (mmHg) 124 137 -13 (-17 to -8) <0.0001 
Diastolic Blood Pressure (mmHg) 75 83 -9 (-12 to -5) <0.0001 
HbA1c (%; percentage points) 6.4 7.8 -1.4 (-1.8 to -1.0) <0.0001 
HbA1c mmol/mol 46 61 -15 (-20 to -11) <0.0001 
Fasting Glucose (mmol/L) 7.2 9.1 -2.0 (-2.9 to -1.1) <0.0001 
GGT (mmol/L) 19.5 26.9 -27.6 (-38.5 to -14.7)% 
# 0.00016 
AST (mmol/L) 20.6 20.5 0.9 (-11.3 to 14.9)% 
# 0.89 
ALT (mmol/L) 24.7 26.0 -5.0 (-19.7 to 12.6)% 
# 0.55 
HDL (mmol/L) 1.24 1.18 0.05 (-0.01 to 0.12) 0.13 
LDL (mmol/L) 2.42 2.24 0.17 (-0.04 to 0.38) 0.106 
Total Cholesterol (mmol/L) 4.14 4.22 -0.07 (-0.36 to 0.19) 0.60 
Triglycerides (mmol/L) 1.00 1.49 -34.3 (-43.4 to -23.7)% 
# <0.0001 
CRP (mmol/L) 3.0 3.5 -12.4 (-30.3 to 10.2)% 
# 0.26 
Medication Effect Score 0.6 2.2 -1.6 (-2.0 to -1.2)
 † NA† 
Leisure Score Index 30.5 25.4 5.1 (-4.3 to 15.3)
 † NA† 
Health Related Quality of Life     
Physical Functioning 72.5 71.8 0.7 (-7.7 to 9.9)
 † NA† 
Role Functioning 88.6 75.0 13.6 (2.4 to 26.3)
 † NA† 
Social Functioning 93.8 87.8 6.1 (-2 to 14.3)
 † NA† 
Mental Health 83.4 76.5 6.9 (1.9 to 12.7)
 † NA† 
Health Perceptions 70.6 51.4 19.2 (13.2 to 25.4) <0.0001 
Pain 28.5 36.0 -7.5 (-17.2 to -0.1) † NA 
Data are adjusted means (Pharm-TCR & TAU) and effect estimates (Treatment Effect) and 95% confidence intervals 
derived from constrained baseline longitudinal analysis via linear mixed models. P-values are from two-sided tests. 
Secondary outcome p-values were not adjusted for multiple comparisons. † bias-corrected and accelerated confidence 
intervals derived from non-parametric bootstrap analysis. #Treatment effect expressed as a percent difference (ratio of 
geometric means) from log-transformed analyses (Pharm-TCR vs. TAU). ‘NA’, a precise P value cannot be obtained for a 
BCa bootstrap analysis. T2D: Type 2 diabetes; BMI: Body mass index; GGT: Gamma-glutamyl transferase; AST: Aspartate 
aminotransferase; ALT: Alanine aminotransferase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; CRP: C-
reactive protein. 




There is mounting evidence that type 2 diabetes can be reversed through nutritional 146 
interventions. What must be considered now is how people with type 2 diabetes can access 147 
efficacious interventions and how healthcare practitioners can safely deploy them. This study 148 
provides RCT level evidence that community-based pharmacists can effectively and safely 149 
implement a dietary intervention that rapidly reduces need for glucose-lowering medications and 150 
improves cardiometabolic health in people with type 2 diabetes within a real-world setting. 151 
 152 
When treating type 2 diabetes, standard clinical practice is to target glucose control and key risk 153 
factors that are associated with the development of micro- and macrovascular disease13. 154 
Cardiovascular disease accounts for ~33-50% of all diabetes related deaths14. In this study, we 155 
demonstrate rapid improvements in glycemic control (while glucose-lowering medications were 156 
withdrawn or reduced), body weight, waist circumference, triglycerides, and blood pressure 157 
following the Pharm-TCR intervention. Furthermore, we report a significant reduction in GGT 158 
levels, which is correlated to reductions in excess liver fat15. Given that excess liver fat is linked 159 
with liver insulin resistance15, and therefore elevated fasting glucose levels, it is unsurprising that 160 
fasting glucose was substantially reduced in the Pharm-TCR group. Taken together, these data 161 
could indicate a depletion of harmful liver fat and a shift toward improved overall metabolic 162 
control. Interestingly, the sizeable reductions in blood pressure occurred despite reduced blood 163 
pressure medication usage in the Pharm-TCR group. The systolic blood pressure reductions in 164 
the Pharm-TCR group equate to a ~25% reduction in total cardiovascular mortality risk16. Post-165 
intervention Pharm-TCR triglyceride levels and the reductions in body weight and waist 166 
circumference have also been linked to meaningful reductions in cardiovascular risk17–19. When 167 
combined with the significant reductions in glycemia, the Pharm-TCR intervention elicited 168 
widespread improvements that would be expected to markedly reduce risk for both micro- and 169 
macrovascular diseases. Several HrQL variables also improved following the Pharm-TCR 170 
intervention, providing evidence of enhanced quality of life. Collectively, these broad health 171 
improvements indicate that the Pharm-TCR intervention is treating the disease rather than just 172 
managing the resulting hyperglycemia. If these improvements are sustained over time, a 173 
reduction in risk for common co-morbidities of type 2 diabetes would be expected. 174 
 175 
Medication changes in clinical trials of similar nutritional interventions (i.e., combined low-176 
carbohydrate, energy-restricted diets) in T2D are often not reported in great detail; however, 177 
Goday et al.20 and Morris et al.21 do report a reduction in medication use as descriptive or 178 
exploratory outcomes. The cardiometabolic health improvements observed in our trial are in line 179 
with HbA1c, weight loss, and changes in lipids in a study led by primary care nurses21 and 180 
physicians20. Taken together, our findings suggest similar efficacy for treatment outcomes in 181 
low-carbohydrate, energy-restricted nutritional interventions implemented in community 182 
pharmacies. 183 
 184 
The exploratory statistical mediation analysis for the HbA1c outcome showed that over half of 185 
the total mean treatment effect was mediated by the change in body mass. Gummesson et al. 22  186 
reported a linear ‘dose-dependent’ relationship between weight loss and HbA1c reduction, with 187 
an estimated mean HbA1c reduction of 0.1 percentage points for each 1 kg of weight loss. In the 188 
current trial, the mean weight loss was approximately 12 kg, which suggests a mean reduction in 189 
HbA1c of around 1.2 percentage points - close to our observed point estimate of 1.4 percentage 190 
points. Nevertheless, only 57% of the mean reduction in HbA1c was mediated by weight loss in 191 
our trial. The direct effect of the intervention (not mediated by weight loss) could be due, in part, 192 
to carbohydrate restriction per se23 although other aspects of glucoregulation (e.g., insulin 193 
sensitivity, beta-cell function) could be involved.  194 
 195 
A specific strength of this study was the use of pharmacists to deliver the nutritional intervention 196 
in the community. The need for rapid medication adjustments (i.e., within days/weeks to avoid 197 
predictable medication related events) when following a low-carbohydrate, low-calorie diet 198 
necessitates that someone knowledgeable in both type 2 diabetes and medication management 199 
has frequent and direct contact with participants. Given the risk of hypoglycemia and 200 
hypotension in this scenario, as well as the frequent visits that people with type 2 diabetes 201 
typically make to their local pharmacy9, community pharmacists were uniquely positioned to fill 202 
this role. Although the intention was not for pharmacists to replace dietitians in delivering 203 
nutrition therapy, they were a suitable choice given the commercial weight loss plan that was 204 
selected to standardize the delivery of the nutritional intervention. This study highlights the 205 
potential of pharmacists in a multidisciplinary health team strategy that includes nutrition 206 
therapy. Given the current burden on primary care physicians in many countries, the lack of 207 
access to registered dietitians, and the fact that people with diabetes typically make 50% more 208 
visits to their pharmacists than their primary care physicians9, future studies should investigate 209 
how a pharmacist-supported care model can be more broadly implemented. 210 
 211 
Recently, studies have reported type 2 diabetes remission as an outcome6,24; however, the criteria 212 
used to define remission are often inconsistent between studies25. The American Diabetes 213 
Association26 has previously suggested criteria for type 2 diabetes remission that was based 214 
primarily on results of bariatric surgery studies. These criteria include the important caveat that 215 
remission of diabetes must demonstrate sustained improvements in glycemia in the absence of 216 
medications or ongoing therapy for at least one year. While a group of participants in this study 217 
did achieve normoglycemia while not taking glucose-lowering medications, the study’s 218 
relatively short duration precludes defining this as type 2 diabetes remission. Recently, Taylor27 219 
used the term post-diabetes to describe individuals who had achieved sub-type 2 diabetes 220 
glycemic levels and ceased using glucose-lowering medications. This is fitting as it implies the 221 
person is no longer in a state of type 2 diabetes but may be at increased risk to redevelop type 2 222 
diabetes due to potentially irreversible pathophysiological alterations that may have already 223 
occurred. The terms remission and reversal both imply that the pathophysiological alterations 224 
contributing to type 2 diabetes (i.e., beta-cell dysfunction and insulin resistance) have improved. 225 
Consequently, without directly measuring these parameters it would be impossible to use these 226 
terms. For this reason, we have chosen not to use these terms to describe our results. Whether the 227 
numerous beneficial improvements in cardiometabolic health observed with the Pharm-TCR 228 
intervention constitute type 2 diabetes reversal, type 2 diabetes remission, or classification of 229 
post-diabetes will require further study. 230 
 231 
Although relatively short-term in duration, there are specific strengths of the study that should be 232 
highlighted. The trial was designed to be pragmatic in nature to allow for insights that could be 233 
beneficial for the implementation of similar interventions in the community. As such, having 234 
community pharmacists deliver the intervention in a RCT design is a major strength of the study. 235 
Furthermore, using a standardized medication deprescription plan allowed for consistent 236 
implementation of the Pharm-TCR intervention in a safe and scalable manner.  237 
 238 
Whilst not unexpected, participant attrition was a limitation to this study. Regardless, we treated 239 
dropouts in both groups as not achieving the primary outcome, so we feel the estimate of the 240 
effect of the intervention is robust. Furthermore, exploratory subgroup analyses suggested that 241 
the mean effect of the intervention was not substantially different between men and women, or 242 
insulin users versus non-users. However, we caution that confidence intervals for these sub-243 
group effects are wide, as the trial was not powered for sub-group interactions. Finally, for 244 
continuous secondary outcomes we utilized a constrained baseline longitudinal analysis via a 245 
linear mixed model28. When there are no missing data, this model is equivalent to a standard 246 
regression model with baseline included as a covariate (ANCOVA). With missing data, the 247 
constrained baseline model is superior, as all participants with at least one measurement 248 
(baseline or post-intervention) are included in the analysis, given that baseline is part of the 249 
outcome vector. Thus, while we do not believe that the loss to follow-up negatively impacted the 250 
robustness of our results, we acknowledge that the attrition rate indicates that this type of 251 
intensive intervention delivered in the community, even while closely supported, might not be 252 
suitable for everyone. 253 
 254 
Although this trial was designed to compare the Pharm-TCR intervention to usual care (i.e., 255 
TAU), some aspects of the design should be emphasized to ensure proper interpretation of the 256 
findings. The Pharm-TCR intervention was given to participants free of charge. It is possible that 257 
this could impact the translation of the results. Furthermore, although a comparison of cost-258 
savings via medication use reduction vs. the cost to implement the intervention is an important 259 
question to be answered in future research, this study was not designed for a cost-effectiveness 260 
analysis. Participants in the Pharm-TCR intervention also received more contact with the study 261 
personnel than participants in the TAU group. As the trial design was pragmatic in nature, the 262 
aim was to compare the Pharm-TCR intervention (which includes both the diet aspect and the 263 
increased monitoring) to usual care. As such, the outcomes in the Pharm-TCR group cannot be 264 
attributed entirely to the effects of the diet alone.  265 
 266 
For a patient with type 2 diabetes, undertaking an impactful dietary change can be potentially 267 
dangerous if not properly informed and/or monitored by qualified healthcare personnel. The 268 
results of this study suggest that pharmacists can fill this role and can help to safely deprescribe 269 
glucose-lowering medications. Future research should investigate the durability of the 270 
cardiometabolic improvements observed and explore ways to optimize delivery of therapeutic 271 
nutrition by incorporating community pharmacists into type 2 diabetes care teams.  272 
 273 
The community pharmacist-led therapeutic carbohydrate- and energy-restricted dietary 274 
intervention effectively improved cardiometabolic health outcomes while safely reducing or 275 
eliminating glucose-lowering medications in patients with type 2 diabetes. Pharmacists could be 276 
viewed as an accessible and innovative option for implementing community-based and 277 
nutritional interventions for people with type 2 diabetes. 278 
 279 
Methods 280 
Study Design and Participants 281 
A pragmatic community-based RCT following a parallel-group design was conducted through 12 282 
community pharmacies (independently owned within the same pharmacy banner) throughout 283 
southern British Columbia, Canada. Ethics approval was granted by UBC Clinical Research 284 
Ethics Board (H16-01539) and written informed consent was obtained from all study participants 285 
prior to enrollment. Study conduct was performed in accordance with the ethical principles 286 
outlined in the World Medical Association Declaration of Helsinki. The trial was registered on 287 
ClinicalTrials.gov (NCT03181165) on June 8th, 2017 and the protocol detailing participant 288 
recruitment, study conduct, and planned data analyses is published elsewhere12. 289 
 290 
Randomization and Blinding  291 
Participants were randomized to either the pharmacist-led, therapeutic carbohydrate-restricted or 292 
treatment-as-usual control groups for 12 weeks. Randomization was performed by the 293 
pharmacist at each site through a secure password-protected website maintained by the Centre 294 
for Health Evaluation and Outcome Sciences (CHEOS). Random allocation was stratified by site 295 
(pharmacy) and glucose-lowering medications (≤2 vs. ≥3 or taking exogenous insulin) and 296 
performed on a 1:1 ratio using variable permuted block sizes. Allocation lists were prepared 297 
using computer generation at CHEOS by a statistician unassociated with the study. Due to the 298 
nature of the trial, it was not possible to blind participants, study personnel at pharmacies, or 299 
research assistants to group allocation. The statistical analysis was also performed unblinded. 300 
 301 
Participant inclusion criteria were: ability to provide written informed consent, age 30-75 years, 302 
type 2 diabetes diagnosis by a physician, using at least one glucose-lowering medication, and a 303 
body mass index of ≥30 kg·m2. Exclusion criteria included: history of a heart attack in the last 304 
two years; current unstable cardiovascular disorder; history of liver disease, kidney disease or 305 
impaired renal function; currently pregnant, lactating or planning to become pregnant within the 306 
next 12 months; diagnosed neurological disorder; history of bariatric surgery; history of cancer 307 
within the last five years; or dietary restrictions that would inhibit adherence to the intervention 308 
diet. 309 
 310 
Study Procedures 311 
Potentially eligible participants were invited to the nearest participating pharmacy to review the 312 
eligibility criteria and study consent form. Recruitment was performed via a combination of 313 
newspaper and online advertising, posters posted in pharmacies, and by word of mouth in each 314 
respective study site location. Prior to any data collection, written informed consent was obtained 315 
and participants’ primary care physicians were notified of their participation. Upon admittance, 316 
eligible participants underwent baseline assessment of medication use, anthropometrics, blood 317 
pressure, and completed study questionnaires measuring HrQL and habitual physical activity 318 
(Godin Leisure-Time Exercise Questionnaire) at the pharmacy.  A fasting blood sample was 319 
obtained by a local laboratory and participants completed a 3-day diet record to assess habitual 320 
food intake.  321 
Participants in the Pharm-TCR group were asked to follow a commercial weight loss diet plan 322 
(Ideal Protein) supplemented with whole foods. The diet plan was provided free-of-charge and 323 
utilized a variety of low-carbohydrate, energy-restricted, adequate-protein meals and snacks that 324 
were used in combination with select meats and vegetables. Based on individualized food 325 
choices selected from within the diet plan, the daily macronutrient content equated to <50g 326 
carbohydrates, ~35-45g fat, and ~110-120g protein for a total of ~850-1100 kcal. Participants in 327 
the Pharm-TCR group had weekly visits to the pharmacy to meet with a lifestyle coach and 328 
pharmacist to monitor progress, collect intervention foods, and assess medication usage. 329 
Lifestyle coaches managed scheduling and administrative tasks and were responsible for 330 
collecting anthropometric and blood pressure data while the pharmacists were responsible for all 331 
disease and medication data collection, information, and decisions. The medication 332 
deprescription plan is outlined in the supplementary information of the published protocol 333 
paper12 (https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3873-7#Sec18). 334 
Data collected at weekly visits included: weight, height (visit 1 only), BMI, waist circumference, 335 
body fat % (bioelectrical impedance analysis), blood pressure, capillary blood ketones, and 336 
medication usage. On week 6 of the diet, participants completed another 3-day diet record. On 337 
the final visit, in addition to the typical weekly assessments, participants were assessed for the 338 
same blood, HrQL, diet record, and habitual physical activity measures that were collected at 339 
baseline. 340 
Participants in the TAU group were given standard medication advice by their pharmacist as well 341 
as information pamphlets on diet and lifestyle conforming with 2013 Diabetes Canada (formerly 342 
the Canadian Diabetes Association) Clinical Practice Guidelines. Participants in the TAU group 343 
did not attend weekly meetings during the 12-week control period; however, they completed a 3-344 
day diet record on week 6, similar to the Pharm-TCR group. Following the 12-week period, TAU 345 
participants returned to the pharmacy where they were assessed for the same blood, 346 
anthropometrics, HrQL, diet record, and habitual physical activity measures that were collected 347 
at baseline. Participants allocated to the TAU group were given the option of receiving the 348 
Pharm-TCR intervention after their initial 12-week TAU period in an effort to retain participants. 349 
 350 
Outcome measures  351 
The primary outcome measure was a binary outcome of either using or not using glucose-352 
lowering medications after the 12-week study period. Secondary outcomes assessed at baseline 353 
and 12 weeks included HbA1c, change in glucose lowering medication dose, BMI, body weight, 354 
waist circumference, body fat percentage, HrQL, blood lipid profile (total, HDL & LDL 355 
cholesterol, triglycerides), liver function tests (ALT, AST, and GGT), fasting plasma glucose, 356 
blood pressure, change in blood pressure medication dose, and a binary outcome of achieving 357 
both HbA1c < 6.5% and no glucose-lowering medication use. Body weight and body fat 358 
percentage were assessed using the Tanita model DF-430 U (IL, USA), blood pressure was 359 
assessed using the PharmaSmart Model PS-2000C (BC, Canada), height was measured using the 360 
Seca model 700 (Germany), and waist circumference was assessed by measuring the distance 361 
around the waist at the top of the iliac crest with a tape measure. HbA1c, fasting plasma glucose, 362 
blood lipid profile, and liver function tests were analyzed by provincially-accredited laboratories 363 
per standard clinical practice. Leisure score index was calculated by multiplying the number of 364 
strenuous, moderate, and mild bouts of physical activity by 9, 5, and 2, respectively29. HrQL was 365 
assessed using the 20-item Medical Outcomes Study Short Form (SF-20) and analyzed as 366 
described in Stewart et al30. Medication effect score was calculated31 as a continuous secondary 367 
outcome to quantify changes in medication use that were not captured by the primary outcome. 368 
Briefly, MES reflects the overall intensity of a diabetes medication regimen and is based on 369 
medication dosages and their efficacy for reducing blood glucose. Secondary outcomes assessed 370 
during the weekly visits in the Pharm-TCR group were MES, BMI, waist circumference, body 371 
fat percentage, systolic blood pressure, and diastolic blood pressure. Descriptive data for 372 
macronutrient content and energy intake from the 3-day food records were analyzed with 373 
MyFitnessPal (Under Armour®, Inc.). 374 
 375 
Statistical Analysis  376 
All analyses were performed using R32 and Stata software33. Data were analyzed as randomized. 377 
For the primary outcome, any participants lost to follow-up were presumed to be still using 378 
glucose-lowering medications. In Stata software, we applied a generalised linear model with a 379 
binomial distribution and logit link, with the Huber/White/sandwich variance estimator. To 380 
permit convergence, given zero events in the TAU arm, we specified the ‘asis’ command. The 381 
difference in proportion (Pharm-TCR vs. TAU) achieving ‘no medications’ and its asymmetric 382 
95% confidence interval was derived using the -regpar- program34. The binary secondary 383 
outcome (both HbA1c <6.5% and ‘no medications’) was analysed with the same model. 384 
Exploratory subgroup analyses by sex and insulin user (yes/ no) were conducted by specifying a 385 
subgroup*treatment interaction. The exploratory subgroup analyses for the primary outcome and 386 
the secondary outcomes of continuous HbA1c and body weight (by sex) are included in 387 
Supplementary Tables 1 and 2. 388 
 389 
For the continuous secondary outcomes, missing data were assumed to be missing at random. 390 
Data were analyzed using constrained baseline longitudinal analysis via a linear mixed model28, 391 
which allows all participants with at least one measurement (baseline or post-intervention) to be 392 
included in the analysis as baseline is part of the outcome vector. The lme4 package35 was used 393 
specifying Satterthwaite degrees of freedom, with fixed effects for timepoint (Pre vs. Post 12-394 
weeks), treatment, sex, and the stratified allocation factors - study site and glucose-lowering 395 
medication use [2 or less, 3 or greater or taking exogenous insulin]) - and a random effect for 396 
participant to account for repeated measures within participants. ‘Treatment’ is a factor coded ‘1’ 397 
if time = post and group = Pharm-TCR and coded zero otherwise. Subgroup analysis by sex was 398 
conducted for HbA1c and body weight by adding a sex*treatment interaction term. For 399 
descriptive purposes, outcomes assessed at the weekly visits in the Pharm-TCR group were 400 
analyzed using a linear mixed model with fixed effects for week (0 to 12), sex, and the 401 
stratification factors (as above), and a random effect for participant.  402 
 403 
Model specification was assessed visually using normal probability plots and residuals vs. fitted 404 
values plots. When the behaviour of the model residuals warranted a log transformation, effect 405 
estimates and 95% confidence intervals were back-transformed to ratio (percentage) differences 406 
using the emmeans package36. In cases where a log transformation could not be used (e.g. due to 407 
zero values), nonparametric bootstrap analyses were performed with 2000 resamples with 408 
replacement, and bias corrected and accelerated 95% confidence intervals were calculated with 409 
the boot package37,38.  410 
 411 
We conducted an exploratory statistical mediation analysis using the Stata -sem- module, to 412 
examine the extent to which the observed treatment effect on HbA1c was mediated by the 413 
change in body mass. This analysis partitions the total causal effect into direct and indirect 414 
effects. The indirect effect is that passing through the putative mediator (change in body mass). 415 
The indirect effect/ total effect × 100 gives the proportion (%) of the total treatment effect 416 
mediated by the change in body mass.  417 
 418 
A sample size of approximately 100 per group was required to provide 80% power to detect a 419 
20% difference (odds ratio of 2.67) in the proportion of patients on zero glucose-lowering 420 
medications (assuming 20% in TAU), with a two-sided P value of 0.0539. Throughout, 95% 421 
confidence intervals are interpreted as the plausible range of effect sizes compatible with the data 422 
and model.  423 
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 561 
  562 
Figure 1: Trial CONSORT flow diagram. Pharm-TCR: Pharmacist-led therapeutic carbohydrate 563 
restriction; TAU: Treatment-as-usual; ITT: Intention-to-treat. Created with BioRender.com. 564 
 565 
Figure 2: Data are weekly effect estimates for changes from baseline (Week 0; gray line) with 566 
confidence intervals in the Pharm-TCR group for a) medication effect score (MES); b) body 567 
mass index; c) waist circumference; d) body fat percentage; e) systolic blood pressure; and f) 568 
diastolic blood pressure. Values are effect estimates for adjusted mean change from baseline in 569 
a-f. Bias-adjusted and accelerated confidence intervals derived from non-parametric bootstrap 570 
analysis are presented in panel a. Error bars for panels b-f represent 95% confidence intervals. 571 
Data are based on participants for which baseline data were collected (n=92) except for waist 572 
circumference (n=90) and body fat percentage (n=91). Source data are provided as a source data 573 
file. 574 
13 pharmacies recruited 
12 pharmacies used for 
recruiting 
1 pharmacy unable to 
continue due to 
staffing 
317 individuals showed initial interest in 
participation 
129 not enrolled 
(not eligible or did 
not respond) 
188 individuals agreed to 
participate and were 
allocated to treatment 
groups 
98 individuals assigned to 
the Pharm-TCR group 
90 individuals assigned to 
the TAU group 
4 participants dropped out 
before commencing the 
Pharm-TCR intervention. 
Reasons: 1 deemed ineligible 
after randomization; 3 lost 
contact 
15 participants dropped 
out before commencing 
the TAU intervention. 
Reasons: 2 deemed 
ineligible after 
randomization; 1 moved 
away; 12 lost contact 
94  commenced the 
Pharm-TCR intervention 
72  commenced the TAU 
intervention 
16 did not complete the 
intervention. Reasons: 2 
family issues; 2 couldn't 
adhere to diet; 2 
unrelated health issues; 
1 travel; 9 lost contact 
15 were lost to 
follow-up. Reasons: 
15 lost contact 
78 completed the 
intervention; 98 included in 
the ITT analysis 
60 completed the 
intervention; 90 included in 
the ITT analysis 
1 pharmacy 
unable to 






























































































1 2 3 4 5 6 7 8 9 10 11 12
Week
E
ffe
ct
 E
st
im
at
e 
(m
m
H
g)
f
